Treatment of Eruptive Lichen Planus

First-Line Treatment Protocol

The American Academy of Dermatology recommends applying clobetasol propionate 0.05% cream or ointment twice daily to affected cutaneous lesions for 2-3 months, followed by gradual tapering over 3 weeks to prevent rebound flares 1, 2
For maintenance, the British Association of Dermatologists suggests using clobetasol propionate 0.05% cream or ointment as needed when symptoms recur, with most patients requiring intermittent application 3, 4

The National Institute for Health and Care Excellence advises using cream or ointment formulations for cutaneous disease, as gel formulations are reserved exclusively for oral mucosal lesions 1, 2
The American Academy of Dermatology recommends applying topical corticosteroids to dried skin for maximum adherence and efficacy, and instructing patients to wash hands thoroughly after application to avoid spreading medication to sensitive areas like eyes or mouth 1, 2, 5

The American Academy of Dermatology suggests that tacrolimus 0.1% ointment can be used as a steroid-sparing alternative when corticosteroids are contraindicated or ineffective 1, 2, 6

For mild to moderate disease, the American Academy of Dermatology recommends starting with high-potency topical corticosteroids (clobetasol 0.05%) twice daily for 2-3 months, and adding oral antihistamines if pruritus is significant 1, 6
For moderate to severe or widespread disease, the American Academy of Dermatology suggests continuing topical corticosteroids as above, adding oral antihistamines for symptom control, and considering a short course of oral prednisone 15-30 mg for 3-5 days for acute severe flares 1, 6

The American Academy of Dermatology advises against abruptly discontinuing topical corticosteroids, and recommends tapering gradually over 3 weeks to prevent rebound flares 1, 2
The National Institute for Health and Care Excellence warns against using gel formulations for cutaneous disease, as gels are only appropriate for oral mucosal lesions 1, 2

The American Academy of Dermatology recommends scheduling follow-up at 3 months to assess treatment response and ensure proper medication use, and monitoring for adverse effects and adjusting dosing based on clinical response 1